NCT01047345 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 618
- group Id
- BG001
- value
- 306
- group Id
- BG002
- value
- 924
- units
- Participants
- groups
- description
- Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
- id
- BG000
- title
- 9vHPV Vaccine - Base Study
- description
- Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
- id
- BG001
- title
- Placebo - Base Study
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 122
- group Id
- BG001
- value
- 60
- group Id
- BG002
- value
- 182
- title
- 12 to 15 years
- categories
- measurements
- group Id
- BG000
- value
- 496
- group Id
- BG001
- value
- 246
- group Id
- BG002
- value
- 742
- title
- 16 to 26 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 618
- group Id
- BG001
- value
- 306
- group Id
- BG002
- value
- 924
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 618
- group Id
- BG001
- value
- 306
- group Id
- BG002
- value
- 924
- units
- Participants
- groups
- description
- Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
- id
- BG000
- title
- 9vHPV Vaccine - Base Study
- description
- Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
- id
- BG001
- title
- Placebo - Base Study
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 122
- group Id
- BG001
- value
- 60
- group Id
- BG002
- value
- 182
- title
- 12 to 15 years
- categories
- measurements
- group Id
- BG000
- value
- 496
- group Id
- BG001
- value
- 246
- group Id
- BG002
- value
- 742
- title
- 16 to 26 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 618
- group Id
- BG001
- value
- 306
- group Id
- BG002
- value
- 924
- title
- Female
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle